CureVac N.V.

NASDAQ:CVAC   3:59:53 PM EDT
17.49
-0.96 (-5.20%)
Products

CureVac And GSK Start Clinical Development Of Second-Generation COVID-19 Vaccine Candidate

Published: 03/30/2022 11:07 GMT
CureVac N.V. (CVAC) - Curevac and Gsk Start Clinical Development of Second-generation Covid-19 Vaccine Candidate, Cv2cov.
Phase 1 Dose-escalation Study Started at Clinical Sites in U.S.milestone Demonstrates Curevac's and Gsk's Continued Execution on Comprehensive Clinical Program of Second-generation Vaccine Candidates for Infectious Diseases.
Data Results From Phase 1 Study Are Expected in Second Half of 2022.